Figure and table legends
FIGURE 1. Study scheme. The patients were selected into or excluded from the study according to the scheme. Representative photographs of C3 immunofluorescence staining. Bar=50μm.
FIGURE 2. Glomerular immunodeposits from the patients in C3low and C3high group. (A, B, D, E, G and H) Representative photographs of glomerular immune complexes deposition (IgA, IgG and IgM) from C3low and C3high group. Bar=50μm. (C, F and I)The difference of glomerular immune complexes deposition (IgA, IgG and IgM) in C3low and C3high group. Glomerular IgA deposition was graded by IgA=2+ and IgA>2+; Glomerular IgG, IgM deposition was graded by absent (score, 0), mild (score, 1), severe (score, 2), respectively. The difference of constituent ratio was analyzed by Chi square test.
FIGURE 3. Morphological characteristics of the biopsies from the patients in C3low and C3high group.(A-F) Representative photographs of PAS staining, Masson staining and electron microscopy from C3low and C3high group. Bar=50μm. The magnification by electron microscopy was 2000 times.
FIGURE 4. C3high group contained more lymphocytes in C3low group in IgAN renal biopsies.A, B, D, E, G, H represent photographs of CD68+, CD4+ and CD8+ cells in C3low and C3high groups. C, F, I showed renal tissues were revealed more CD68+, CD4+ and CD8+ cells infiltration in the C3high group. Box plots indicated statistical differences. Values greater than 95% or less than 5% is listed as a dot while values less than 95% or greater than 5% were hidden in positive and negative error line. The line in the center of each box represents the median value, and the upper and lower ends of the box are the upper and lower quartiles, Bar=50μm.
FIGURE 5. Renal survival curve of creatinine doubling and ESRD. (A) Kaplan-Meier estimates of proportion of renal survival (absence of creatinine doubling) in 83.3% (85/102) v.s. 61.8% (21/34) of the patients in C3low and C3high group, respectively. Estimated overall survival time were 97.8 (95% CI:93.4-102.2) months for patients in C3low group; 81.9 (95% CI: 70.7–93.0) months for patients in C3high group, P=0.025 (log rank test). (B) Kaplan-Meier estimates of proportion of renal survival (absence of ESRD) in 93.1 % (95/102) v.s. 67.6% (23/34) of the patients in C3low and C3high group, respectively. Estimated survival time were 100.2 (95% CI: 96.4-104.1) months for patients in C3low group; 86.5 (95% CI: 75.9–97.0) months for patients C3high group, P=0.002 (log rank test).